Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 16/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505046 | 0.94 | GRM5 (0.74) | GRM5KCNH2 | |
| SCHEMBL30785574 | 0.75 | GRM5 (0.45) | GRM5KCNH2 | |
| SCHEMBL30794682 | 0.74 | GRM5 (1.00) | GRM5KCNH2 | |
| SCHEMBL10253573 | 0.74 | ADCY1 (0.45) | GRM5HSD11B1 | |
| SCHEMBL3665854 | 0.73 | GRM5 (0.45) | GRM5KCNH2 | |
| SCHEMBL24969391 | 0.73 | GRM5 (1.00) | GRM5KCNH2 | |
| SCHEMBL28766815 | 0.72 | S1PR5 (0.46) | GRM5KCNH2 | |
| SCHEMBL173734 | 0.72 | GRM5 (0.90) | GRM5 | |
| SCHEMBL160794 | 0.71 | GRM5 (0.76) | GRM5KCNH2 | |
| SCHEMBL10250246 | 0.71 | GRM5 (0.44) | GRM5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | GRM5 1/4885KCNH2 3375/4885TACR3 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.